Stockscreener 앱 받기
21.62
1.95%
-0.43
전일 마감가:
$22.05
열려 있는:
$22.26
하루 거래량:
901.05K
Relative Volume:
0.90
시가총액:
$2.58B
수익:
$460.48M
순이익/손실:
$142.80M
주가수익비율:
18.32
EPS:
1.18
순현금흐름:
$221.79M
1주 성능:
-7.09%
1개월 성능:
-5.67%
6개월 성능:
+5.62%
1년 성능:
+57.70%
1일 변동 폭
$21.35
$22.27
1주일 범위
$21.35
$23.59
52주 변동 폭
$13.49
$24.64
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
명칭
Catalyst Pharmaceuticals Inc
전화
(305) 529-2522
주소
355 ALHAMBRA CIRCLE, CORAL GABLES
CPRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
21.62 | 2.58B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-04 | 개시 | Robert W. Baird | Outperform |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-03-14 | 개시 | Citigroup | Buy |
| 2024-03-07 | 개시 | BofA Securities | Buy |
| 2023-12-21 | 개시 | Oppenheimer | Outperform |
| 2022-08-24 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-07 | 재개 | Piper Jaffray | Overweight |
| 2016-10-05 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | 재확인 | ROTH Capital | Buy |
| 2014-09-16 | 재확인 | ROTH Capital | Buy |
| 2014-09-15 | 재확인 | H.C. Wainwright | Buy |
| 2013-10-21 | 재확인 | Aegis Capital | Buy |
| 2013-09-24 | 개시 | Maxim Group | Buy |
| 2013-09-06 | 재확인 | Aegis Capital | Buy |
| 2013-04-18 | 개시 | Aegis Capital | Buy |
| 2012-08-27 | 업그레이드 | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | 업그레이드 | Merriman | Sell → Neutral |
| 2009-05-29 | 다운그레이드 | Hapoalim | Neutral → Underperform |
| 2009-05-29 | 다운그레이드 | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | 개시 | Merriman Curhan Ford | Buy |
| 2007-11-28 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | 개시 | Stifel Nicolaus | Buy |
| 2007-01-05 | 개시 | First Albany | Buy |
모두보기
Catalyst Pharmaceuticals Inc 주식(CPRX)의 최신 뉴스
Cautious Investors Not Rewarding Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Performance Completely - Simply Wall St
Allspring Global Investments Holdings LLC Boosts Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Average Rating of "Buy" by Brokerages - MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stake Raised by Allspring Global Investments Holdings LLC - Defense World
Catalyst Pharmaceuticals (CPRX) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Allspring Global Investments Holdings LLC Has $8.71 Million Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Catalyst Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals stock hits all-time high of $24.44 - MSN
Those who invested in Catalyst Pharmaceuticals (NASDAQ:CPRX) five years ago are up 374% - Yahoo Finance
Yousif Capital Management LLC Has $903,000 Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Advisors Preferred LLC Takes $1.08 Million Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025 - GlobeNewswire
Catalyst Pharmaceuticals to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025 - Nasdaq
Earnings Alert: Catalyst Pharmaceuticals Sets Key Q4 Financial Results DateStrategic Updates Expected - StockTitan
abrdn plc Acquires Shares of 484,666 Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Bought by Spire Wealth Management - MarketBeat
Catalyst Pharmaceuticals (NASDAQ:CPRX) Raised to "Strong-Buy" at Baird R W - MarketBeat
Short Interest in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Rises By 12.5% - MarketBeat
Catalyst Pharmaceuticals (NASDAQ:CPRX) Coverage Initiated by Analysts at Robert W. Baird - MarketBeat
Catalyst Remains a Big Money Favorite - FX Empire
Robert W. Baird Initiates Coverage on Catalyst Pharmaceuticals (NASDAQ:CPRX) - Defense World
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Baird Initiates Coverage of Catalyst Pharmaceuticals (CPRX) with Outperform Recommendation - MSN
Baird starts Catalyst Pharma with Outperform, $28 target - MSN
This Expand Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Baird Initiates Coverage on Catalyst Pharmaceuticals With Outperform Rating, $28 Price Target - Marketscreener.com
Beyond The Numbers: 6 Analysts Discuss Catalyst Pharmaceuticals Stock - Benzinga
SG Americas Securities LLC Buys 24,102 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock Price Up 5.4%Time to Buy? - MarketBeat
Catalyst Pharmaceuticals (NASDAQ:CPRX) Hits New 12-Month HighWhat's Next? - MarketBeat
CPRX: 3 Niche Healthcare Stocks Tackling Rare Diseases - StockNews.com
Nilsine Partners LLC Invests $700,000 in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Moody Aldrich Partners LLC Trims Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
EMC Capital Management Has $308,000 Stock Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Bought by SG Americas Securities LLC - Defense World
Catalyst Pharmaceuticals stock hits all-time high of $24.44 By Investing.com - Investing.com Australia
Catalyst Pharmaceuticals Inc (CPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.27%
3.05%
자본화:
|
볼륨(24시간):